tiprankstipranks

FDA grants traditional approval to Keytruda for HER2-positive GEJ

FDA grants traditional approval to Keytruda for HER2-positive GEJ

On March 19, the Food and Drug Administration granted traditional approval to pembrolizumab, or Keytruda, marketed by Merck (MRK), with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1. Pembrolizumab previously received accelerated approval for this indication on May 5, 2021, based on interim analysis of a previous trial.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Questions or Comments about the article? Write to editor@tipranks.com